The Chu Lab is focused on uncovering novel mechanisms and therapeutic targets in the diagnosis and treatment of childhood liver disease. Our group examines the role of sugar metabolism pathways in the regulation of liver development and disease with particular focus on liver fibrosis.
During her fellowship training, Dr. Chu led efforts to develop the first pre-clinical zebrafish model of congenital disorders of glycosylation, which are pediatric diseases with prominent liver disease. We use this model to dissect the novel intersection between induction of the tumor suppressor, p53, sugar metabolism, and protein glycosylation. Our current research investigates metabolic mechanisms of hepatic stellate cell activation in liver fibrosis and development of novel targeted therapies to dampen the fibrogenic response.